AI news ·
Quotient Sciences begins first clinical trial of an AI-designed oral drug formulation
Quotient Sciences has started what it calls the first Phase I clinical trial of an AI-designed oral drug formulation, with MHRA approval to test it in healthy volunteers at its Nottingham site.
AI-Designed Drug Formulation Advances to Clinical Testing
Quotient Sciences has initiated a Phase I clinical study of an oral drug formulation designed using artificial intelligence, marking what the company says is the first time an AI-designed drug product has entered human testing.
The UK-based contract research and manufacturing organization received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to begin the study at its Nottingham facility. Researchers will evaluate the safety and pharmacokinetics of the formulation in healthy volunteers.
The study uses machine learning algorithms developed by Intrepid Labs to optimize the drug's formulation design. The AI approach allowed the team to rapidly test multiple formulation options and make decisions based on data rather than traditional trial-and-error methods.
What This Means for Product Development
For product development professionals, the milestone demonstrates a practical application of AI for Product Development in a heavily regulated industry. The approach combines computational design with real-world clinical validation.
Andy Lewis, Chief Scientific Officer at Quotient Sciences, said the method "enables our customers to make earlier, more informed decisions with greater confidence, ultimately increasing the likelihood of clinical success."
The company integrated the AI-driven formulation work with its existing Translational Pharmaceutics platform, which combines formulation development, manufacturing, and clinical testing in a single workflow. This integration reduces the typical silos between departments that slow drug development.
Broader Strategy
Quotient Sciences plans to expand the use of AI across its formulation development and clinical workflows. The company expects to release additional data and results over the coming months as the study progresses.
The Phase I study serves as a validation test for machine learning in pharmaceutical development. Success here could influence how other organizations approach formulation design and early-stage drug development decisions.
For more information, visit Quotient Sciences.